Latest News
Celator Pharmaceuticals gets European Patent Allowance for taxane prodrug nanoparticle delivery technology
19 December 2014 - Biopharmaceutical company Celator Pharmaceuticals (NasdaqCM:CPXX) reported on Thursday that it has received the European Patent Office's allowance for its "Improved Taxane Delivery System" with patent protection for formulations combining docetaxel and other taxanes with molecularly targeted agents.

The patent, which has been assigned the new patent European patent number 2,222,278, covers the company's proprietary taxane prodrug nanoparticle delivery technology and CPX-8, a hydrophobic docetaxel prodrug nanoparticle, which is based on this innovative approach to drug delivery.

According to the company, the nanoparticle-based delivery technology provides versatile control of the pharmacokinetics and tissue accumulation of taxanes such as paclitaxel and docetaxel. This patent provides protection until November 2028.

Login
Username:

Password: